Myelofibrosis Excellence Forum

Myelofibrosis

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Zilurgisertib Alone or Combined With Ruxolitinib Well-Tolerated Among Patients With Myelofibrosis

07/25/2024

Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.

Prithviraj Bose, MD, shares...

07/25/2024

Oncology

Videos

Examining Real-World Outcomes Among Patients With Myelofibrosis Treated With Pacritinib

07/17/2024

John Mascarenhas, MD, shares results of a retrospective study on the real-world treatment outcomes among patients with myelofibrosis who were treated with pacritinib.

John Mascarenhas, MD, shares...

07/17/2024

Oncology

Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust

Q&As

Elritercept Well-Tolerated, Demonstrates Potential Efficacy for the Treatment of Patients With Myelofibrosis

07/11/2024

Claire Harrison, MD, FRCP, shares results of the ongoing phase 2 RESTORE trial in which elritercept was generally well-tolerated and demonstrated potential efficacy for treating patients with myelofibrosis.

Claire Harrison, MD, FRCP,...

07/11/2024

Oncology

Videos

Novel Updates in Frontline Myelofibrosis Treatment Research

06/25/2024

Aaron Gerds, MD, discusses data from the MANIFEST-2 and TRANSFORM-1 trials exploring first-line treatment options for patients with myelofibrosis, as well as analyzes the establishment of optimal clinical trial end points.

Aaron Gerds, MD, discusses data...

06/25/2024

Oncology

Videos

Examining Luspatercept Efficacy for Anemia and Transfusion Burden Among Patients With Myelofibrosis

06/24/2024

Aaron Gerds, MD, presents insights into data from a study in which luspatercept improved anemia and transfusion burden for patients with myelofibrosis, and explains next steps for investigating luspatercept in further clinical trials.

Aaron Gerds, MD, presents...

06/24/2024

Oncology

Marina Kremyanskaya, MD, PhD, Icahn School of Medicine

Videos

Rusfertide Improves Hematocrit Control and Decreases Use of Phlebotomy Among Patients With PV

05/28/2024

Featuring Marina Kremyanskaya, MD, PhD

Featuring Marina Kremyanskaya, MD, Ph...

Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.

Marina Kremyanskaya, MD, PhD,...

05/28/2024

Oncology

Q&As

Preventing Transformation and Adverse Events Among Patients With Myelofibrosis

03/07/2024

Featuring Eytan M Stein, MD

Eytan M Stein, MD, shares expert insights on preventing transformation and reducing the symptom burden of adverse events among patients with myelofibrosis.

Eytan M Stein, MD, shares expert...

03/07/2024

Oncology

Q&As

Evaluating Efficacy and Safety of Pelabresib Among Patients With MDS/MPN

03/07/2024

Featuring Eytan M Stein, MD

Eytan M Stein, MD, discusses findings from the MANIFEST trial which evaluated the efficacy and safety of pelabresib among patients with acute leukemia, high-risk myelodysplastic syndrome, or MDS/MPN.

Eytan M Stein, MD, discusses...

03/07/2024

Oncology

Videos

Assessing Efficacy of Jaktinib Among Ruxolitinib-Intolerant Patients With Myelofibrosis

02/21/2024

Featuring Jie Jin, MD, PhD

Jie Jin, MD, PhD, shares results from a phase 2 study that explored the efficacy of Janus kinase inhibitor jaktinib treatment for ruxolitinib-intolerant patients with myelofibrosis.

Jie Jin, MD, PhD, shares results...

02/21/2024

Oncology

Q&As

Encouraging Developments in Treatment Strategy for Patients With Myelofibrosis

02/21/2024

Featuring Francesca Palandri, MD, PhD

Featuring Francesca Palandri, MD, PhD...

Francesca Palandri, MD, PhD, discusses future possibilities and new breakthroughs in treatment strategies for patients with myelofibrosis, such as expanding treatment options for high-risk patients and more deeply considering the biology of...

Francesca Palandri, MD, PhD,...

02/21/2024

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology